New Data Shows Benefit of Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Hormone-Sensitive Prostate Cancer

Results from the Phase 3 PSMAddition trial, published in The Lancet, indicate that adding lutetium Lu 177 vipivotide tetraxetan to androgen deprivation therapy and an androgen receptor pathway inhibitor significantly extended radiographic progression-free survival in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.